Ketamine Hydrochloride

NEW YORK, Oct. 6, 2025 /PRNewswire/ -- NYU Langone Health has announced Joshua Berman, MD, PhD, a renowned leader in complex psychiatric treatment, as the new director for its interventional psychiatry services. Dr. Berman comes to NYU Langone from Columbia University Medical Center, boasting a decades-long career in treating patients with the latest available therapies. Continue Reading Joshua A. Berman, MD, PhD Dr. Berman's primary mission will be to build a state-of-the art interventional psychiatry program, which involves fully comprehensive treatments for a variety of conditions, as well as multiple treatment modalities. There is opportunity, using collaboration between clinicians and researchers available across the NYU Langone Health system, to create a cutting-edge service where providers can translate research from the lab to treatments in a clinical setting rapidly and safely. "NYU Langone Health has all the pieces necessary to rapidly put this kind of program together. We have specialists and researchers in psychedelics, neuromodulation, and novel pharmacotherapies," said Dr. Berman. "Most importantly, we have a nimble collaborative environment where we can effectively and efficiently implement new kinds of clinical care." Interventional psychiatry is a specialty within the field of psychiatry that targets the brain directly, using electrical, magnetic, and pharmacological therapies to improve symptoms in conditions such as treatment-resistant depression, bipolar disorder, and other severe psychiatric illnesses. Therapies may include treatments that involve direct brain stimulation via devices that cannot be taken home or used by the patient unassisted, or treatments that may be given under anesthesia or may involve altered states that require periods of close monitoring. "Dr. Berman has a long and successful career, and we are honored to have him join us," said Charles R. Marmar, MD, the Peter H. Schub Professor of Psychiatry and chair of the Department of Psychiatry at NYU Grossman School of Medicine. "His leadership and expertise in building this ambitious interventional psychiatry service will further our commitment to providing the best outcomes for patients with severe and complex psychiatric conditions." About Dr. Berman Dr. Berman's clinical career has centered on interventional psychiatry, particularly electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), deep brain stimulation, and the use of ketamine and esketamine for treatment-resistant depression. He has led major hospital services, including Columbia's inpatient and continuation ECT program and its ketamine service. Dr. Berman served as an associate professor of psychiatry at Columbia University Medical Center and medical director of the Interventional Neurotherapeutic Psychiatry Program. He earned his AB in molecular biophysics and biochemistry from Yale University, followed by a PhD in neurobiology and an MD from the Mount Sinai School of Medicine. He completed his internship and residency at New York Presbyterian Hospital and the New York State Psychiatric Institute, then pursued postdoctoral fellowships in affective disorders and substance abuse research at Columbia University. His research has explored molecular neurobiology, nicotine and stress pathways, and clinical trials in neuromodulation. He has served as site principal investigator for multicenter studies, including trials of deep TMS and deep brain stimulation for depression, as well as industry partnerships developing MRI-guided TMS approaches. Dr. Berman is widely published, with work appearing in Lancet Psychiatry, World Psychiatry, and the Journal of Neurochemistry. He has also contributed to textbooks on mood disorders and ECT, and he is an active mentor and educator, developing training programs in interventional psychiatry for residents and fellows. About NYU Langone Health: NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient, Inc., has ranked NYU Langone No. 1 out of 118 comprehensive academic medical centers across the nation for four years in a row, and U.S. News & World Report recently ranked four of its clinical specialties number one in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise. Media Inquiries Ryan Dziuba [email protected] 212-404-4131 SOURCE NYU Langone Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW YORK, Oct. 6, 2025 /PRNewswire/ -- At a time where research funding is being cut across the country in healthcare systems, universities and more, advancing suicide prevention work is more critical than ever. As the largest private funder of suicide prevention research in the United States and globally, the American Foundation for Suicide Prevention (AFSP) continues to prioritize funding research and shaping suicide prevention strategies. Today, AFSP announced 36 new research grants totaling $8.5 million, making the organization's total research investment in FY 2026 more than $30 million. These grants address six key suicide research areas: (1) Neurobiology, (2) Genetics, (3) Psychosocial contributors, (4) Clinical Treatment, (5) Surviving suicide loss and (6) Community Intervention. Find the full list of grants awarded here . Some areas examined by the newest grants include: Novel treatments for sleep disturbance for suicidal young adults. Using care data and machine learning to identify youth and adults at risk for suicide. Examining the contributions of genetics and brain function to suicidal thoughts and behaviors. Learning more about suicide risk in neurodivergent youth. Understanding the immune mechanisms underlying the anti-suicidal effects of ketamine and ECT. Studying and addressing the impact of minority stress on suicidal thoughts and behavior in among those in the LGBTQ+ community. Gaining insights into the effects of public health policies on suicide rates among youth in rural America. Developing and testing several brief interventions for suicidal youth, some as young as elementary school age. Determining the impact of maternal mental health medication use in pregnancy and offspring suicidal behavior. Addressing suicidal thoughts, behaviors and quality of life among suicide bereaved Asians. Research continues to inform every facet of AFSP's work including its awareness building and educational programs, nationwide advocacy efforts and support for those affected by suicide. Through grant funding, recruiting and training researchers and sharing our findings with the public, AFSP is creating a culture that's smart about mental health. "We must continue funding research when lives are at stake," said AFSP Senior Vice President of Research Dr. Jill Harkavy-Friedman. "We are committed to continuing to raise the funds needed to support innovative research that helps us save and improve the lives of people who face mental health struggles." In 2019, AFSP funded a standard research grant that sought to uncover biomarkers (measurable indicators of the presence of a disease or condition) that may be associated with suicide risk and the mental health conditions most associated with it. This study, conducted by researcher, Dr. Adolfo Sequeira and colleagues, is the first study to explore suicide specific gene expression changes both in blood and brain tissue in subjects with Major Depressive Disorder (MDD). This study is part of the vision to one day be able to predict suicide risk through blood biomarkers and demonstrates how research plays a significant role in making groundbreaking discoveries and the needed development of treatment options in the field of suicide prevention. The research grants are funded mainly through small individual donations from participants who attend AFSP Out of the Darkness Walks. The grants are awarded globally, and many of the researchers receive subsequent funding from the National Institute of Mental Health and other large funding agencies. AFSP's investments are guided by its Scientific Council, composed of leading suicide prevention experts, and by the priorities set by the National Strategy for Suicide Prevention. In 2023 and 2024, AFSP co-hosted the Suicide Research Symposium, a free virtual research conference where early career researchers presented alongside seasoned researchers. The organization will also co-host the 2025 International Summit on Suicide Research along with the International Academy of Suicide Research. AFSP also hosted the third Mentoring Immersion for Early Career Researchers Program, bringing together early career researchers and their mentors to revise their grant applications. AFSP welcomes applications in all areas of suicide research and sets priorities to stimulate research in typically understudied areas. Funding research that helps to understand and prevent suicide in underrepresented communities and populations with higher rates is core to this effort. The organization is committed to mentoring and supporting promising researchers focusing on these communities. To learn more about suicide prevention research, visit afsp.org/research. The American Foundation for Suicide Prevention is dedicated to saving lives and bringing hope to those affected by suicide, including those who have experienced a loss. AFSP creates a culture that's smart about mental health through public education and community programs, develops suicide prevention through research and advocacy, and provides support for those affected by suicide. Led by CEO Robert Gebbia and headquartered in New York, with a public policy office in Washington, DC, AFSP has local chapters in all 50 states, DC and Puerto Rico, with programs and events nationwide. Learn more about AFSP in its latest Annual Report and join the conversation on suicide prevention by following AFSP on Facebook, Twitter, Instagram, YouTube, LinkedIn and TikTok. Please fill out this press request form with media inquiries and review AFSP's Ethical Reporting Tips. Media Contact: [email protected] SOURCE American Foundation for Suicide Prevention WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED